Government Support Aids in Realizing Potential of EPO Biosimiliar Market
Due to unprecedented patent expirations and certain financial crisis, government across the world has been pushing the availability of EPO biosimilars at a much discounted rate in the market in a way to reduce the healthcare costs. For Instance, CEO of biotechnology Industry organization has promoted company’s biosimilar bill to provide them access to biologic medicines. Besides, EMA has planned to introduce risk management plans to lead the world in biosimilar regulation. This in turn increases the prescriber’s confidence and...
View full press release